A.N. NIKOLAEV, V.G. DEMIKHOV, V.L. DOBIN, N.V. INYАKOVA, E.PH.MORSCHAKOVA
Ryazan Regional Clinical TB Dispensary
Ryazan branch of the Federal Scientific and Clinical Center of Children Hematology, Oncology and Immunology named after D. Rogachev
Ryazan State Medical University named after I.P. Pavlov

Nikolaev Alexey Nikolaevich
physician and thoracic surgeon
33г Novoselov Str., apt.114, Ryazan 390048
tel. 8-920-638-96-21, e-mail: nalex12@mail.ru

The study included 22 patients with pulmonary tuberculosis and presumptive hemoglobin level post surgery of less than 120 g/l. For the prevention of postoperative anemia was used the recombinant human erythropoietin alpha and iron (III) hydroxide sucrose complex. Within four weeks level of hemoglobin after surgery and the need for blood transfusions was accessed. Use of recombinant human erythropoietin and iron sucrose in patients with pulmonary tuberculosis increases basic hematological parameters as compared with the control group, and reduces the risk of postoperative anemia.

Key words: postoperative anemia, recombinant erythropoietin, tuberculosis, surgery.

REFERENCES

1. Chang H., Hall G.A., Geerts W.H. et al. Allogeneic red blood cell transfusion is an independent risk factor for the development of postoperative bacterial infection //Vox Sang. — 2000. — Vol. 78. — Р. 13-18.

2. Innerhofer P., Luz G., Spotl L. et al. Immunologic changes after transfusion of autologous or allogeneic buffy coat poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells // Transfusion. — 1999. — Vol. 39. — Р. 1089-1096.

3. Landers D.F., Hill G.E., Wong K.C. et al. Blood transfusion-induced immunomodulation // Anesth Analg. — 1996. — Vol. 82. — Р. 187-204.

4. Faris P.M., Ritter M.A., Abels R.I. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation // The American Erythropoietin Study Group. J Bone Joint Surg Am. — 1996. — Vol. 78. — Р. 62-72.

5. Laupacis A., Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomizedtrials. The International Study of Peri-operative Transfusion (ISPOT) Investigators // Transfus. Med. — 1998. — Vol. 8. — Р. 309-317.

6. Lofthouse R.A., Boitano M.A., Davis J.R. et al. Preoperative administration of epoetin alfa to reduce transfusion requirements in elderly patients having primary total hip or knee reconstruction // J South Orthop. Assoc. — 2000. — Vol. 9. — Р. 175-181.

7. Weber E.W.G., Slappendel R., Hеmon Y. et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST) // European Journal of Anaesthesiology. — 2005. — Vol. 22. — Р. 249-257.

8. Spahn D.R. Eliminating blood transfusions. New aspects and perspectives // Anesthesiology. — 2000. — Vol. 93. — Р. 242-255.

9. Yazicioglu L., Eryilmaz S., Sirlak M. et al. Recombinant human erythropoietin administration in cardiac surgery // J Thoac. Cardiovasc. Surg. — 2001. — Vol. 122. — Р. 741-745.

10. Demihov V.G., Injakova N.V., Kravcova N.B. i dr. Ispol’zovanie rekombinantnogo jeritropojetina dlja lechenija anemii pri tuberkuleze legkih (pilotnoe issledovanie) // Tuberkulez i bolezni legkih. — 2011. — № 11. — S. 26-30.

11. Nikolaev A.N., Demihov V.G., Dobin V.L. i dr. Sposob prognozirovanija razvitija posleoperacionnoj anemii pri planovyh torakal’nyh operacijah u bol’nyh tuberkulezom // V poiskah optimal’nyh reshenij: novye idei v hirurgii i travmatologii RGMU. — 2011. — S. 45-47.